{"nctId":"NCT01346293","briefTitle":"Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age","startDateStruct":{"date":"2011-04"},"conditions":["Tetanus","Diphtheria","Pertussis","Measles","Polio"],"count":3372,"armGroups":[{"label":"Study Group 1","type":"EXPERIMENTAL","interventionNames":["Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus"]},{"label":"Study Group 2","type":"EXPERIMENTAL","interventionNames":["Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus"]},{"label":"Study Group 3","type":"EXPERIMENTAL","interventionNames":["Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus"]},{"label":"Study Group 4","type":"EXPERIMENTAL","interventionNames":["Biological: Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus"]}],"interventions":[{"name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus","otherNames":["DTap-IPV","M-M-R®II","VARIVAX®"]},{"name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus","otherNames":["DAPTACEL®","IPOL®","M-M-M R®II","VARIVAX®"]},{"name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus","otherNames":["DTap-IPV","M-M-R®II","VARIVAX®"]},{"name":"Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus","otherNames":["DAPTACEL®","IPOL®","M-M-R®II","VARIVAX®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged ≥ 4 to \\< 7 years on the day of inclusion\n* Informed consent form has been signed and dated by the parent/guardian before the first study-related procedure\n* Subject and parent/guardian are able to attend all scheduled visits and to comply with all trial procedures\n* Subject has documented completion of primary infant series and booster with DAPTACEL® and/or Pentacel® vaccine(s) only.\n\nExclusion Criteria:\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the trial vaccination\n* Planned participation in another clinical trial during the present trial period\n* Receipt of any vaccine in the 4 weeks preceding the trial vaccination, except for any influenza vaccine, which may be received at least 2 weeks before study vaccines\n* Planned receipt of any vaccine in the 4 weeks following the trial vaccination except for any influenza vaccine, which may be received at least 2 weeks after study vaccines\n* Receipt of blood or blood-derived products in the past 3 months\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C\n* History of diphtheria, tetanus, or pertussis infection, confirmed either clinically, serologically, or microbiologically\n* Known systemic hypersensitivity to any of the vaccines' components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances\n* Laboratory-confirmed thrombocytopenia, contraindicating intramuscular vaccination\n* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination\n* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion\n* Identified as employees of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the employees or the investigator.","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Years","maximumAge":"6 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Booster responses to pertussis antigens \\[pertussis toxoid (PT), filamentous hemagglutinin (FHA), pertactin (PRN), and fimbriae types 2 and 3 (FIM)\\] were measured by enzyme-linked immunosorbent assay (ELISA). Booster responses were defined as participants with either a pre-vaccination antibody concentration less than lower limit of quantitation (\\<LLOQ), achieving a post-vaccination level ≥4X LLOQ, or pre-vaccination antibody concentrations ≥LLOQ but \\<4X LLOQ, achieving a 4-fold rise rate of post-vaccination, or a pre-vaccination antibody concentration ≥4X LLOQ, achieving a 2-fold response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"240","spread":null},{"groupId":"OG001","value":"222","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":null},{"groupId":"OG001","value":"217","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"246","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"243","spread":null},{"groupId":"OG001","value":"230","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Geometric mean concentrations to pertussis antigens (pertussis toxoid \\[PT\\], filamentous hemagglutinin \\[FHA\\], pertactin \\[PRN\\], and fimbriae types 2 and 3 \\[FIM\\]) were measured by enzyme-linked immunosorbent assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.16","spread":null},{"groupId":"OG001","value":"4.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.93","spread":null},{"groupId":"OG001","value":"9.42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"123","spread":null},{"groupId":"OG001","value":"79.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"283","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.9","spread":null},{"groupId":"OG001","value":"33.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"506","spread":null},{"groupId":"OG001","value":"379","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Booster Response to Tetanus and Diphtheria Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Anti-Tetanus antibodies were measured by enzyme-linked immunosorbent assay (ELISA). Anti-Diphtheria antibodies were measured by a toxin neutralization test. Booster responses were defined as participants with a pre-vaccination antibody concentration \\<0.1 IU/ml, achieving a post-vaccination level ≥0.4 IU/ml, or a pre-vaccination antibody concentration ≥0.1 IU/ml but \\<2.0 IU/ml, achieving a 4-fold rise rate post-vaccination, or a pre-vaccination antibody concentration ≥2.0 IU/ml, achieving a 2-fold response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"209","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"249","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentrations of the Tetanus and Diphtheria Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Geometric mean concentrations to anti-tetanus and anti-diphtheria were measured by enzyme-linked immunosorbent assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.644","spread":null},{"groupId":"OG001","value":"0.608","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.42","spread":null},{"groupId":"OG001","value":"5.48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.510","spread":null},{"groupId":"OG001","value":"0.426","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"15.5","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Booster Response to Polio Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Anti-poliovirus types 1, 2, and 3 titers were measured by neutralization assay. Booster responses were defined as participants with a pre-vaccination antibody concentration \\<1:8 dil, achieving a post-vaccination level ≥1:8 dil, or a pre-vaccination antibody concentration ≥1:8 dil, achieving a 4-fold response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null},{"groupId":"OG001","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"196","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"210","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentrations of Polio Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Geometric mean concentrations to anti-polio were measured by enzyme-linked immunosorbent assay (ELISA).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3477","spread":null},{"groupId":"OG001","value":"2731","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"214","spread":null},{"groupId":"OG001","value":"188","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3491","spread":null},{"groupId":"OG001","value":"3894","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"102","spread":null},{"groupId":"OG001","value":"90.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4591","spread":null},{"groupId":"OG001","value":"3419","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Seroprotection Against the Tetanus and Diphtheria Antigens Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Anti-Tetanus antibodies were measured by ELISA. Anti diphtheria antibodies were measured by a toxin neutralization test. Seroprotection for anti-tetanus and anti-diphtheria was defined as antibody concentrations ≥0.1 IU/ml and ≥1.0 IU/ml.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null},{"groupId":"OG001","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"93","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"262","spread":null},{"groupId":"OG001","value":"251","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"259","spread":null},{"groupId":"OG001","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"233","spread":null},{"groupId":"OG001","value":"207","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"262","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"261","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Seroprotection Against the Polio Antigens Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Anti-Poliovirus types 1, 2, and 3 titers were measured by neutralization assay. Seroprotection for anti-polio types was defined as antibody titers ≥1:8 dilution.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"250","spread":null},{"groupId":"OG001","value":"245","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"253","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"253","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"244","spread":null},{"groupId":"OG001","value":"231","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"258","spread":null},{"groupId":"OG001","value":"252","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Booster Response to the Polio Antigens Following Vaccination With Inactivated Poliovirus (IPV) Vaccine as a 4th or 5th Dose","description":"Anti-Poliovirus types 1, 2, and 3 titers were measured by neutralization assay. Four-fold rise in booster responses between groups was defined as post/pre-vaccination ≥4.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":null},{"groupId":"OG001","value":"199","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"203","spread":null},{"groupId":"OG001","value":"202","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Summary of Anti-Polio Geometric Mean Titers in Participants That Received Inactivated Poliovirus (IPV) Vaccine as a 4th and 5th Dose","description":"Anti-Poliovirus types 1, 2, and 3 titers were measured by neutralization assay.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134","spread":null},{"groupId":"OG001","value":"123","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3471","spread":null},{"groupId":"OG001","value":"2774","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"194","spread":null},{"groupId":"OG001","value":"342","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3327","spread":null},{"groupId":"OG001","value":"1773","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"210","spread":null},{"groupId":"OG001","value":"181","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3495","spread":null},{"groupId":"OG001","value":"3991","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"274","spread":null},{"groupId":"OG001","value":"431","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3566","spread":null},{"groupId":"OG001","value":"2048","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.5","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4773","spread":null},{"groupId":"OG001","value":"3500","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"323","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1663","spread":null},{"groupId":"OG001","value":"2436","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine","description":"Solicited injection-site: Pain, Erythema, Swelling, Extensive Swelling of Vaccinated Limb, Change in Limb Circumference. Solicited systemic reactions: Fever (Temperature), Headache, Malaise, and Myalgia. Grade 3 injection-site: Pain, Incapacitating, unable to perform usual activities; Erythema, Swelling, ≥50 mm; Change in limb circumference \\>50 mm increase over pre-vaccination measurement; Extensive limb swelling (ELS) was considered severe. Grade 3 systemic reactions: Fever ≥39.0˚C; Headache, Malaise, and Myalgia Significant, prevents daily activity.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2081","spread":null},{"groupId":"OG001","value":"461","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1587","spread":null},{"groupId":"OG001","value":"322","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"484","spread":null},{"groupId":"OG001","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1076","spread":null},{"groupId":"OG001","value":"219","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1703","spread":null},{"groupId":"OG001","value":"302","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"161","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"419","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"940","spread":null},{"groupId":"OG001","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1445","spread":null},{"groupId":"OG001","value":"317","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":21,"n":2733},"commonTop":["Injection site Pain","Change in limb circumference","Injection site Erythema","Myalgia","Injection site Swelling"]}}}